Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

243 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Neoadjuvant Immune-Checkpoint Blockade in Triple-Negative Breast Cancer: Current Evidence and Literature-Based Meta-Analysis of Randomized Trials.
Marinelli D, Mazzotta M, Pizzuti L, Krasniqi E, Gamucci T, Natoli C, Grassadonia A, Tinari N, Tomao S, Sperduti I, Sanguineti G, Botticelli A, Fabbri A, Botti C, Ciliberto G, Barba M, Vici P. Marinelli D, et al. Among authors: sanguineti g. Cancers (Basel). 2020 Sep 3;12(9):2497. doi: 10.3390/cancers12092497. Cancers (Basel). 2020. PMID: 32899209 Free PMC article.
Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios.
Pizzuti L, Krasniqi E, Barchiesi G, Mazzotta M, Barba M, Amodio A, Massimiani G, Pelle F, Kayal R, Vizza E, Grassadonia A, Tomao S, Venuti A, Gamucci T, Marchetti P, Natoli C, Sanguineti G, Ciliberto G, Vici P. Pizzuti L, et al. Among authors: sanguineti g. J Cancer. 2019 Oct 12;10(24):5903-5914. doi: 10.7150/jca.35109. eCollection 2019. J Cancer. 2019. PMID: 31762800 Free PMC article. Review.
Observational Multicenter Study on the Prognostic Relevance of Coagulation Activation in Risk Assessment and Stratification in Locally Advanced Breast Cancer. Outline of the ARIAS Trial.
Pizzuti L, Krasniqi E, Mandoj C, Marinelli D, Sergi D, Capomolla E, Paoletti G, Botti C, Kayal R, Ferranti FR, Sperduti I, Perracchio L, Sanguineti G, Marchetti P, Ciliberto G, Barchiesi G, Mazzotta M, Barba M, Conti L, Vici P. Pizzuti L, et al. Among authors: sanguineti g. Cancers (Basel). 2020 Apr 1;12(4):849. doi: 10.3390/cancers12040849. Cancers (Basel). 2020. PMID: 32244657 Free PMC article.
Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives.
Barchiesi G, Mazzotta M, Krasniqi E, Pizzuti L, Marinelli D, Capomolla E, Sergi D, Amodio A, Natoli C, Gamucci T, Vizza E, Marchetti P, Botti C, Sanguineti G, Ciliberto G, Barba M, Vici P. Barchiesi G, et al. Among authors: sanguineti g. Int J Mol Sci. 2020 May 16;21(10):3528. doi: 10.3390/ijms21103528. Int J Mol Sci. 2020. PMID: 32429381 Free PMC article. Review.
Role of Chemotherapy in Vulvar Cancers: Time to Rethink Standard of Care?
Mazzotta M, Pizzuti L, Krasniqi E, Di Lisa FS, Cappuzzo F, Landi L, Sergi D, Pelle F, Cappelli S, Botti C, Vizza E, Tomao S, Marchetti L, Sanguineti G, Botticelli A, Marchetti P, Magri V, Pisegna S, Venuti A, Tomao F, Buzzacchino F, Ciliberto G, Barba M, Vici P. Mazzotta M, et al. Among authors: sanguineti g. Cancers (Basel). 2021 Aug 12;13(16):4061. doi: 10.3390/cancers13164061. Cancers (Basel). 2021. PMID: 34439215 Free PMC article. Review.
The Impact of the Hippo Pathway and Cell Metabolism on Pathological Complete Response in Locally Advanced Her2+ Breast Cancer: The TRISKELE Multicenter Prospective Study.
Krasniqi E, Di Lisa FS, Di Benedetto A, Barba M, Pizzuti L, Filomeno L, Ercolani C, Tinari N, Grassadonia A, Santini D, Minelli M, Montemurro F, Fabbri MA, Mazzotta M, Gamucci T, D'Auria G, Botti C, Pelle F, Cavicchi F, Cappelli S, Cappuzzo F, Sanguineti G, Tomao S, Botticelli A, Marchetti P, Maugeri-Saccà M, De Maria R, Ciliberto G, Sperati F, Vici P. Krasniqi E, et al. Among authors: sanguineti g. Cancers (Basel). 2022 Oct 3;14(19):4835. doi: 10.3390/cancers14194835. Cancers (Basel). 2022. PMID: 36230758 Free PMC article.
Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives.
Krasniqi E, Barchiesi G, Pizzuti L, Mazzotta M, Venuti A, Maugeri-Saccà M, Sanguineti G, Massimiani G, Sergi D, Carpano S, Marchetti P, Tomao S, Gamucci T, De Maria R, Tomao F, Natoli C, Tinari N, Ciliberto G, Barba M, Vici P. Krasniqi E, et al. Among authors: sanguineti g. J Hematol Oncol. 2019 Oct 29;12(1):111. doi: 10.1186/s13045-019-0798-2. J Hematol Oncol. 2019. PMID: 31665051 Free PMC article. Review.
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience.
Vici P, Pizzuti L, Michelotti A, Sperduti I, Natoli C, Mentuccia L, Di Lauro L, Sergi D, Marchetti P, Santini D, Magnolfi E, Iezzi L, Moscetti L, Fabbri A, Cassano A, Grassadonia A, Omarini C, Piacentini F, Botticelli A, Bertolini I, Scinto AF, Zampa G, Mauri M, D'Onofrio L, Sini V, Barba M, Maugeri-Saccà M, Rossi E, Landucci E, Tomao S, Alberti AM, Giotta F, Ficorella C, Adamo V, Russo A, Lorusso V, Cannita K, Barni S, Laudadio L, Greco F, Garrone O, Della Giulia M, Marolla P, Sanguineti G, Di Cocco B, Ciliberto G, De Maria R, Gamucci T. Vici P, et al. Among authors: sanguineti g. Oncotarget. 2017 May 25;8(34):56921-56931. doi: 10.18632/oncotarget.18176. eCollection 2017 Aug 22. Oncotarget. 2017. PMID: 28915642 Free PMC article.
Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting.
Mandoj C, Pizzuti L, Sergi D, Sperduti I, Mazzotta M, Di Lauro L, Amodio A, Carpano S, Di Benedetto A, Botti C, Ferranti F, Antenucci A, D'Alessandro MG, Marchetti P, Tomao S, Sanguineti G, Giordano A, Maugeri-Saccà M, Ciliberto G, Conti L, Vici P, Barba M. Mandoj C, et al. Among authors: sanguineti g. J Transl Med. 2018 May 16;16(1):129. doi: 10.1186/s12967-018-1511-x. J Transl Med. 2018. PMID: 29769125 Free PMC article.
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study.
Gamucci T, Pizzuti L, Natoli C, Mentuccia L, Sperduti I, Barba M, Sergi D, Iezzi L, Maugeri-Saccà M, Vaccaro A, Magnolfi E, Gelibter A, Barchiesi G, Magri V, D'Onofrio L, Cassano A, Rossi E, Botticelli A, Moscetti L, Omarini C, Fabbri MA, Scinto AF, Corsi D, Carbognin L, Mazzotta M, Bria E, Foglietta J, Samaritani R, Garufi C, Mariani L, Barni S, Mirabelli R, Sarmiento R, Graziano V, Santini D, Marchetti P, Tonini G, Di Lauro L, Sanguineti G, Paoletti G, Tomao S, De Maria R, Veltri E, Paris I, Giotta F, Latorre A, Giordano A, Ciliberto G, Vici P. Gamucci T, et al. Among authors: sanguineti g. Cancer Biol Ther. 2019;20(2):192-200. doi: 10.1080/15384047.2018.1523095. Epub 2018 Nov 7. Cancer Biol Ther. 2019. PMID: 30403909 Free PMC article.
243 results